US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

(Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ...

Jan. 1, 2025 — Researchers have traced a cellular route Ebola virus (EBOV) uses to traverse the inner and outer layers of skin and emerge onto the skin's surface. The study identifies new cell ...

Cincinnati Bengals wide receiver Tee Higgins has stepped into the injury limelight once again. This time, it’s a knee injury for Higgins as his Bengals get ready to take on the Cleveland Browns in ...

(KRON) — A 6-year-old boy who ran onto Interstate 280 in San Jose on Friday night was struck and killed by a passing vehicle, according to the California Highway Patrol. On Monday, the Santa ...